Browse the corpus

©2013 UpToDate ® Print Email Clinical associations of autoantibodies in SLE Antigen specificity Clinical associations Prevalence, percent* dsDNA Marker for active disease, titers fluctuates with disease activity, correlates best with renal disease 40-60 ssDNA Nonspecific, no clinical utility 70 Ro/SSA Subacute cutaneous lupus (75 percent), photosensitivity, neonatal lupus, complement deficiencies 40 RNP (U1-RNP) SLE generally in conjunction with Sm; in MCTD, required for diagnosis 30-40 La/SSB With La, low prevalence of renal disease Neonatal lupus (75 percent) 10-15 Sm Marker for disease, not generally useful in management; May be associated with CNS disease About 20 Phospholipids Hypercoagulable state in some patients. No clinical significance in others. Thrombocytopenia, later trimester abortions 30 Histones >95 percent in drug-related lupus. Also present in RA, SLE, reported insystemic sclerosis with pulmonary fibrosis Ribosomal P Initially associated withpsychosis in SLE, more recently with depression 10-40 KU SLE, MCTD (European, American population) Scleroderma/myositis overlap (Japanese population) ≤19 , ≤39 PCNA 3 * Rates vary depending on technique used.